Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) is expected to be posting its results before the market opens on Monday, May 11th. Analysts expect Catheter Precision to post earnings of ($20.90) per share and revenue of $1.60 million for the quarter.
Catheter Precision Stock Up 1.2%
Shares of VTAK stock traded up $0.01 on Monday, reaching $0.96. 54,260 shares of the company’s stock traded hands, compared to its average volume of 861,758. Catheter Precision has a 12-month low of $0.79 and a 12-month high of $15.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.08 and a current ratio of 0.10. The company has a market capitalization of $2.59 million, a P/E ratio of -0.05 and a beta of -1.04. The business’s 50 day moving average price is $1.21 and its two-hundred day moving average price is $1.79.
Institutional Trading of Catheter Precision
An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC purchased a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent SEC filing. 20.34% of the stock is currently owned by hedge funds and other institutional investors.
About Catheter Precision
Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.
All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.
Further Reading
Receive News & Ratings for Catheter Precision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catheter Precision and related companies with MarketBeat.com's FREE daily email newsletter.
